Fractyl Health Shares Plunge After Midpoint REMAIN-1 Data on Revita Weight Maintenance
Fractyl Health's stock dropped roughly 35% after the company released six-month randomized midpoint results from its REMAIN-1 study assessing Revita for weight maintenance following GLP-1 discontinuation. Revita-treated patients showed less weight regain than the sham arm at six months and improvements in certain cardiometabolic lipid markers, but …